Biotech Values

[DewDiligence]

BioMS – As noted in my prior post, I find it more plausible that a drug could work well in RRMS but not SPMS than the reverse situation where a drug worked well in SPMS but not RRMS. Thus, I consider BioMS’ failure in RRMS to be a modest but non-trivially bearish harbinger for the SPMS program.